Drug intelligence / Profile preview

CGB-600

Development stage: Phase 1
Lead developer: CAGE Bio
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Topical

Overview

CGB-600 is an investigational DNA aptamer therapy developed by CAGE Bio, licensed from TAGCyx Biotechnologies. It is designed as a topical treatment for vitiligo, specifically nonsegmental facial vitiligo. The drug functions by selectively binding to and neutralizing interferon gamma (IFN-γ), a key cytokine involved in the autoimmune destruction of melanocytes, thereby downregulating autoimmune activity. CAGE Bio utilizes its proprietary ionic liquid drug delivery platform, originating from the University of California, Santa Barbara, to enable non-invasive topical delivery of this large nucleic acid drug into the skin. CGB-600 is currently in Phase 2 clinical trials.

Targets

IFNG (Interferon gamma)

Beyond the preview

Go deeper on CGB-600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGB-600.

Explore the full profile